|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
WednesdayExpanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS MeetingDr. Rhonda Voskuhl, M.D. Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Rhonda Voskuhl, M.D., the lead investigator of the Phase II clinical trial evaluating Trimesta™, the Company's oral product candidate for the treatment of relapsing-remitting multiple sclerosis (MS), is scheduled to present additional clinical outcome data, including more detailed results on cognitive and disability measures. The data will be presented at the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS) in Boston. Read more » Labels: Trimesta |